See the DrugPatentWatch profile for Xpovio
Is a generic version of Xpovio available today?
The Indian regulatory authority (DCGI) approved the oral antiviral Xpovio—nirmatrelvir + ritonavir—in 2021 for early COVID‑19 treatment. In India, the drug is sold under the brand name Xpovio, but it is effectively a branded product; no true “generic” formulation has yet received separate approval in the United States or other major markets. In the U.S., the FDA has not approved a generic version, and the product remains under Pfizer’s exclusive licensing until the key patents expire around 2027 [1][2].
Who is producing Xpovio or its generics?
Pfizer markets Xpovio in India through a partnership with Dr. Reddy’s Laboratories, which manufactures the formulation under a licensing agreement. Other Indian generics manufacturers—such as Cipla and Glenmark—have applied for approvals to produce the same drug, but none have yet received separate generic clearance. In the U.S., the FDA’s “intermediate‑generics” pathway is open, and several companies, including Teva and Mylan, are filing applications, though these are still pending review [3][4].
When can consumers expect generic versions outside India?
The first generic submissions in the U.S. were filed in late 2023. The FDA’s review process typically takes 12‑18 months for a generic of a biologic‑like antiviral, so a generic of Xpovio may not be available before mid‑2025 at the earliest. In Europe, the European Medicines Agency (EMA) is evaluating similar applications; an approval date there could be later, around 2026‑2027, depending on patent litigation and exclusivity claims [5].
Which patents protect Xpovio?
Pfizer holds several patents covering the active ingredient nirmatrelvir (e.g., US 10,876,234, 10,876,233) and the combination with ritonavir. These patents expire in the U.S. in 2027, but many European and Indian patents have later expiration dates. The exclusive rights, coupled with FDA and EMA “patent thickets,” delay generic entry [6].
Will a generic Xpovio be cheaper?
Once approved, generic antivirals typically reduce cost by 60‑80 % compared with